DOI:
10.1055/s-00050348
Indian Journal of Medical and Paediatric Oncology
LinksClose Window
References
Reck M, Mok TS, Nishio M, Jotte RM, Cappuzzo F, Orlandi F. et al.
Atezolizumab plus bevacizumab and chemotherapy in non-small-cell lung cancer (IMpower150): Key subgroup analyses of patients with EGFR mutations or baseline liver metastases in a randomised, open-label phase 3 trial.
Lancet Respir Med 2019;
7: 387-401
We do not assume any responsibility for the contents of the web pages of other providers.